drugset / Trial / NCT07318389
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Timeline
- Start
- 2026-06-10
- Primary completion
- 2027-11-14
- Completion
- 2029-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Adagrasib | Small molecule | — | Oral |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |
| Background | Encorafenib | Small molecule | — | Oral |
| Background | Panitumumab | Monoclonal antibody | — | Intravenous |
| Background | Sotorasib | Small molecule | — | Oral |
| Background | Tipiracil | Small molecule | — | Oral |
| Background | Trastuzumab deruxtecan | Monoclonal antibody | — | Intravenous |
| Background | Trifluridine | Small molecule | — | Oral |
| Background | Tucatinib | Small molecule | — | Oral |